Related Experiment Video
Updated: Nov 11, 2025
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
15.2K
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for
Pavlo Holenya1, Paul Joris Lange2,3,4,5, Ulf Reimer1
1JPT Peptide Technologies GmbH, Berlin, Germany.
European Journal of Immunology
|March 27, 2021
Summary
Antibodies targeting the Severe Adult Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) show cross-reactivity with other human coronaviruses. Specific SARS-CoV-2 peptides can distinguish between COVID-19 patients and controls, aiding diagnostic test development.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- Humoral immunity to SARS-CoV-2 is vital for protection but not fully understood.
- Antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) has significant implications for immunity and diagnostics.
Purpose of the Study:
- To investigate antibody cross-reactivity between SARS-CoV-2 and other HCoVs.
- To identify specific SARS-CoV-2 antigens for diagnostic test development.
Main Methods:
- Peptide microarrays were used to screen 24 COVID-19 patient samples and 12 control samples.
- Antibodies were tested against the SARS-CoV-2 proteome and specific proteins (Spike, Nucleocapsid, VME1, R1ab, Protein 3a) from SARS-CoV-2 and HCoVs (SARS, MERS, OC43, 229E).
Main Results:
- Widespread antibody cross-reactivity was observed across immunodominant regions of Spike (S) and Nucleocapsid (N) proteins.
- Specific SARS-CoV-2 peptides demonstrated statistically significant IgG binding differences between COVID-19 patients and controls.
Conclusions:
- Selected SARS-CoV-2 peptides can differentiate COVID-19 patients from controls.
- These peptides hold potential as capture antigens for developing specific diagnostic antibody tests for COVID-19.
